Tamoxifen

Tamoxifen (brand names Nolvadex, Soltamox) is best known for treating and preventing breast cancer in women, blocking estrogen receptors in some tissues while acting estrogen-like in others. It's a small-molecule oral drug, not a peptide. It's FDA-approved for the breast-cancer use; there's no FDA-approved use in men. Off-label, it's used for conditions like gynecomastia and as post-cycle therapy after anabolic steroid use, though the post-cycle pattern isn't backed by randomized trials.

Tamoxifen is used to treat and prevent breast cancer, with one of the largest trial evidence bases of any cancer medicine: landmark trials established that it reduces breast-cancer recurrence and that 10 years of treatment further reduces mortality versus 5 years. It's FDA-approved for that use. In men it is studied and used off-label for gynecomastia (multiple studies including randomized trials support this, with a generally favorable safety profile at typical doses); its use after androgen cycles (post-cycle therapy) is widespread but not supported by randomized trials.

FDA-approved as Nolvadex (tamoxifen citrate) under NDA 017970 — originally approved December 30, 1977 (one of the first 50 oncology drugs ever approved by the FDA), originally for treatment of advanced breast cancer in postmenopausal women. Subsequent FDA-approved indication expansions: adjuvant treatment of node-positive breast cancer (1986); adjuvant treatment of node-negative ER-positive breast cancer in postmenopausal women (1990, supported by nsabp b-14 trial); reduction of breast cancer incidence in high-risk premenopausal and postmenopausal women (1998, supported by nsabp p-1 trial); ductal carcinoma in situ (DCIS) (2000). Generic tamoxifen became widely available in 2002 following patent expiration. Branded products currently marketed include Nolvadex (AstraZeneca historical, now generic-equivalent) and Soltamox (oral solution formulation, FDA-approved 2005). Tamoxifen is FDA-approved exclusively for indications in women — there is no FDA-approved tamoxifen indication in men, including for gynecomastia or PCT-style HPG-axis recovery. Off-label use in men is widespread and supported by published RCTs in specific contexts (bicalutamide-induced gynecomastia prophylaxis in prostate cancer; idiopathic gynecomastia treatment) but is not within the FDA-approved label. Not DEA-scheduled. WADA-banned in regulated sport — explicitly named under Section S4.2 (Anti-Estrogenic Substances and SERMs) of the 2026 Prohibited List as a Specified Substance.

Tamoxifen is a prescription-only medication and is banned in WADA-tested sport; its label carries serious warnings in women (including endometrial cancer and blood-clot risk), and clot risk in men is plausible but less well characterized. VialWise is a research and educational reference, not medical advice — consult a licensed professional.

⚠️ For research and educational purposes only. Tamoxifen (Nolvadex) is FDA-approved exclusively for breast-cancer indications in women. Use in men — for gynecomastia treatment/prevention, post-cycle therapy (PCT) HPG-axis recovery, or other off-label purposes — is off-label and operates outside FDA approval. Information in this entry is informational, not medical advice. Always consult appropriate professional guidance before any protocol decisions.

⚠️ Tamoxifen is not a peptide. Oral tablet. Calculator is informational, not computational. Same framing as Anastrozole and Clomiphene/Enclomiphene — Tamoxifen is a small-molecule SERM dosed as or oral tablets (Nolvadex, generic) or as/5 mL oral solution (Soltamox). The Vialwise calculator's role for tamoxifen is to display the labeled and off-label dosing patterns plus the SERM/AI cluster cross-references — there is no per-injection draw to compute.

⚠️ Navigate the SERM/AI cluster carefully — Tamoxifen, Clomiphene/Enclomiphene, Anastrozole, and Letrozole are all related TRT-adjunct compounds with substantially different pharmacology and use cases. This is the third TRT-adjunct entry in the library; readers should understand the cluster: - Tamoxifen (this entry) — SERM. Tissue-selective estrogen receptor antagonist/agonist. Strongest off-label men's-health evidence base for gynecomastia treatment and prevention (multiple published RCTs in bicalutamide-induced gynecomastia; multiple cohort studies in idiopathic gynecomastia). Also used for pct hpg-axis recovery. Long half-life (~5–7 days for parent + 14 days for endoxifen) means daily dosing is sufficient. - Clomiphene/Enclomiphene — SERMs. Hypothalamic-selective estrogen receptor antagonist (less estrogenic-agonist activity at non-hypothalamic tissues than tamoxifen). Strongest off-label men's-health evidence base for hypogonadism and as TRT alternative (Huijben 2022 meta-analysis). Sometimes preferred over tamoxifen for HPG-axis stimulation specifically because of the cleaner antagonist profile at the hypothalamus. - Anastrozole and Letrozole — Aromatase inhibitors (AIs). Mechanistically distinct from SERMs — instead of blocking estrogen receptors, they block aromatase (the enzyme that converts androgens to estrogens), reducing estrogen production. Used as TRT adjunct to manage aromatization-driven estradiol elevation. Note from Anastrozole entry: the Burnett-Bowie 2009 RCT established that AIs reliably normalize serum testosterone in older hypogonadal men but do not consistently improve clinical outcomes — the clinical-utility-gap finding. SERMs like clomiphene and tamoxifen have more favorable men's-health-outcome evidence than AIs do. The "FDA-approved indication is in women; off-label use is in men" sub-pattern continues — fourth instance after Anastrozole, Clomiphene/Enclomiphene, and now Tamoxifen.

⚠️ Black-box warnings — the safety profile in women includes serious risks; the men's-health off-label safety profile is generally more favorable but is less well-characterized in published literature. The FDA Nolvadex label carries black-box warnings for: - Endometrial cancer and uterine sarcoma in women — tamoxifen's partial agonist activity at the endometrium drives a meaningful (~2–4×) increased risk of endometrial cancer in women on long-term tamoxifen. This black-box warning does not apply to men (men do not have endometrium). - Stroke and pulmonary embolism in women — increased risk of venous thromboembolism (VTE), pulmonary embolism (PE), and ischemic stroke in women on tamoxifen. VTE risk in men on off-label tamoxifen is less well-characterized but the underlying pharmacology is shared and theoretical risk is plausible. Researchers with personal or family history of VTE should be cautious. Other notable safety considerations: Hot flashes (very common across all populations); mood and cognitive effects (variable); bone density preservation in postmenopausal women (favorable, due to partial agonist activity at bone) but uncertain in men; lipid effects (favorable HDL changes, less consistent LDL effects); cataracts (uncommon but characteristic class effect for triphenylethylene SERMs — same as clomiphene); ocular effects including the same visual-disturbance concerns as clomiphene (uncommon); CYP2D6 metabolism interactions (see About). The Wibowo 2016 *Andrology* review of adverse events in men on tamoxifen characterized the off-label men's-health safety profile across published cohorts and case reports — generally favorable at typical men's-health dosing, with hot flashes as the most common reported adverse event.[⁵]

⚠️ WADA-banned — explicitly named under Section S4.2 as a Specified Substance. Tamoxifen is one of the named compounds in the canonical 2026 WADA Prohibited List Section S4.2 (Anti-Estrogenic Substances and SERMs), alongside Bazedoxifene, Elacestrant, Raloxifene, Clomifene, Fulvestrant, Cyclofenil, Ospemifene, and Toremifene.[⁶] Specified Substance status under WADA's framework means a positive test triggers a reduced sanction range vs non-Specified Substances — but the compound remains prohibited at all times, in-competition and out-of-competition. Same WADA subsection (S4.2) as Clomiphene/Enclomiphene — second SERM entry in the library, third entry in the broader S4 (Hormone and Metabolic Modulators) WADA cluster after Anastrozole's S4.1.

Tamoxifen is the prototype triphenylethylene-class selective estrogen receptor modulator (SERM) and one of the most-prescribed cancer drugs in history. The compound was originally synthesized as ICI 46,474 in 1962 by Dora Richardson at the ICI Pharmaceuticals chemistry laboratories (now AstraZeneca) within a project to develop a contraceptive pill. The compound was found to stimulate (rather than suppress) ovulation in women — failing the original contraceptive goal — but Arthur Walpole's research team pivoted the program to develop tamoxifen as a treatment for breast cancer.[¹] Tamoxifen received UK approval in 1973 for metastatic breast cancer, and US FDA approval on December 30, 1977 (NDA 017970) for advanced breast cancer in postmenopausal women.[¹]

Mechanism. Tamoxifen's mechanism is tissue-selective estrogen receptor modulation — antagonist activity at some tissues (particularly breast), partial agonist activity at others (uterus/endometrium, bone, liver). The tissue-selectivity drives both the therapeutic mechanism (breast tissue antagonism for breast cancer treatment/prevention) and the major adverse effects (endometrial-tissue partial agonism for endometrial cancer / uterine sarcoma risk in women). Tamoxifen is a prodrug — the parent compound has modest receptor affinity, but the CYP2D6-mediated metabolite endoxifen has ~100-fold higher ER affinity and 30–100× more potency than the parent. CYP2D6 metabolizer status (poor, intermediate, extensive, ultrarapid) substantially affects endoxifen formation and may influence clinical response, particularly in breast-cancer treatment contexts. Strong CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion, quinidine) reduce endoxifen levels and may reduce tamoxifen's clinical effect.

FDA-approved evidence base (breast cancer). Tamoxifen has one of the largest RCT evidence bases of any oncology drug: - nsabp b-14 (Fisher 1989, NEJM) — the pivotal trial supporting the 1990 adjuvant approval for node-negative ER-positive breast cancer in postmenopausal women. 2,644 patients randomized to tamoxifen twice daily or placebo for 5 years.[²] - nsabp p-1 / Breast Cancer Prevention Trial (Fisher 1998, JNCI) — the trial supporting the 1998 chemoprevention indication for breast cancer in high-risk women. ~13,000 women randomized. - nsabp b-24 — supported the DCIS indication - ibis-I / ibis-II — chemoprevention trials in high-risk women - EBCTCG meta-analyses (Early Breast Cancer Trialists' Collaborative Group) — pooled analyses across multiple decades and many trials, establishing that 5 years of tamoxifen reduces breast cancer recurrence by approximately half and mortality by approximately one-third in ER-positive disease - ATLAS (Davies 2013, Lancet) — 6,846 women with ER-positive breast cancer who had been on tamoxifen for 5 years randomized to continue for another 5 years vs stop. Continuing tamoxifen to 10 years rather than stopping at 5 produces further reductions in recurrence and mortality, particularly after year 10, approximately halving breast cancer mortality during the second decade after diagnosis.[³] This trial drove the modern shift from 5-year to 10-year adjuvant tamoxifen practice. - aTTom — companion trial to ATLAS with similar design and findings

Off-label use in men — published evidence base. Tamoxifen is the SERM with the strongest published off-label men's-health evidence base, particularly for gynecomastia:

- Bicalutamide-induced gynecomastia prophylaxis in prostate cancer patients — multiple RCTs (Boccardo 2005; Saltzstein 2007 dose-response RCT) established that tamoxifen prevents and treats gynecomastia and breast pain in prostate cancer patients on bicalutamide monotherapy. The most rigorous published off-label men's-health evidence base for any SERM in any indication. - Idiopathic gynecomastia treatment — the largest prospective cohort (Mannu et al. 2018, PMID 30079473; 81 men over 10 years) reported complete resolution in 90.1% (73/81) on tamoxifen daily; 8 men did not fully resolve and 2 of those went on to surgery.[⁴] *(A frequently repeated "lump-type responds better than fatty-type, 100% vs 62.5%" comparison is not present in that cohort's published record and no primary source for it has been located.)* - Pubertal gynecomastia — used off-label in adolescent boys with persistent pubertal gynecomastia. Generally well-tolerated; no RCT-grade evidence in pubertal populations specifically. - PCT (post-cycle therapy) HPG-axis recovery in research-community AAS contexts — widely used in research-community PCT protocols for 4–6 weeks post-cycle. Mechanism: blocks estrogen-receptor-mediated negative feedback on the hypothalamus, increasing endogenous LH/FSH/T production. No RCT-grade evidence specifically for AAS-PCT contexts — extrapolation from breast-cancer pharmacology and the broader serm hpg-axis-stimulation literature.

Wibowo 2016 *Andrology* review of adverse events in men on tamoxifen synthesized the published off-label men's-health safety experience across cohorts and case reports.[⁵] The off-label men's-health safety profile is generally favorable at typical doses, with hot flashes as the most-commonly-reported adverse event. The endometrial-cancer black-box warning that defines the safety concern in women is not relevant in men. The VTE black-box warning concern remains plausible but is less well-characterized in published men's-health literature.

Regulatory status (US — current). Tamoxifen is FDA-approved exclusively for breast-cancer indications in women (advanced, adjuvant, prevention, DCIS). All use in men — including gynecomastia treatment, PCT, and other men's-health contexts — is off-label. Off-label prescribing is legal in the US under standard FDA prescribing-authority framework but is not supported by FDA-approved labeling. Generic tamoxifen is widely available since 2002 patent expiration. Standard prescription required (not DEA-scheduled).

Regulatory status (sport — WADA). Tamoxifen is named explicitly under Section S4.2 (Anti-Estrogenic Substances and SERMs) of the 2026 WADA Prohibited List as a Specified Substance, alongside Bazedoxifene, Elacestrant, Raloxifene, Clomifene, Fulvestrant, Cyclofenil, Ospemifene, and Toremifene.[⁶] Same WADA subsection as Clomiphene/Enclomiphene. Prohibited at all times.

Common research interests. Despite the off-label status for all men's-health uses, tamoxifen is among the most-used SERMs in research-community contexts: - Gynecomastia treatment and prevention — the dominant research-community use case in men. Strongest published off-label evidence base of any SERM for any men's-health indication. - PCT (post-cycle therapy) for HPG-axis recovery after AAS cycles — widely used; no RCT-grade evidence specifically for this indication. - Adjunct to TRT for estradiol management (less common than anastrozole or clomiphene for this purpose) — tamoxifen can be used to manage gynecomastia symptoms during TRT but is less commonly chosen than anastrozole (which suppresses estrogen synthesis) or clomiphene (which has cleaner hypothalamic-antagonist profile). - Breast cancer treatment and prevention in women — the FDA-approved use case. Clinical use under specialist oncology supervision; not a research-community use case.

Commonly reported

• Hot flashes — most common reported side effect across all populations; typically mild-to-moderate.
• Mood and cognitive effects — variable; commonly reported but inconsistent across patients.
• Headache, fatigue — uncommon to moderate.
• Nausea, vomiting — uncommon.
• Vaginal discharge or dryness (women) — common; not relevant in men.
• Cataracts — uncommon; characteristic class effect for triphenylethylene SERMs (same as clomiphene).
• Visual disturbances — uncommon but characteristic class effect; warrants prompt discontinuation and ophthalmologic evaluation.
• Lipid changes — variable; favorable HDL changes commonly reported.
• Bone density preservation in postmenopausal women (favorable) — partial agonist activity at bone receptors.
• Hot flashes — most common in men as well.
• Mood symptoms (irritability, mild depression) — variable.
• Decreased libido — uncommon at typical men's-health doses; more commonly reported at higher doses.
• No consistent pattern of serious adverse events in the published men's-health literature at typical dosing for 3–12 month durations.
• VTE risk in men — less well-characterized than in women; underlying pharmacology suggests theoretical risk.
• Long-term safety in men beyond 1–2 years — not well characterized.
• CYP2D6 metabolism interactions — strong CYP2D6 inhibitors reduce endoxifen formation and may reduce clinical effect.

Serious

• Endometrial cancer and uterine sarcoma — increased risk in women; ~2–4× incidence vs placebo in long-term use. Annual gynecologic monitoring for women on tamoxifen.
• Stroke and pulmonary embolism — increased risk of VTE, PE, ischemic stroke in women on tamoxifen.

Pregnancy — Pregnancy Category D; embryotoxicity in animal studies. Documented absence of pregnancy required before initiating in females of reproductive potential.

Hypersensitivity to tamoxifen or any product excipient.

Concurrent warfarin in patients with DCIS or for breast cancer prevention (FDA label-specific contraindication; relative contraindication in other contexts with INR monitoring).

History of deep vein thrombosis or pulmonary embolism (in patients receiving tamoxifen for breast cancer prevention or DCIS).

Endometrial cancer and uterine sarcoma risk (women) — black-box warning.

VTE/PE/stroke risk (women) — black-box warning.

Visual disturbances — discontinue immediately for any visual changes; evaluate before considering re-treatment.

Hepatic effects — rare hepatic toxicity reported; monitor LFTs.

CYP2D6 metabolism considerations — strong CYP2D6 inhibitors reduce endoxifen formation.

Lactation — not recommended.

Regulatory note (US): Tamoxifen is FDA-approved exclusively for breast-cancer indications in women. All use in men is off-label. Generic widely available since 2002. Standard prescription required (not DEA-scheduled).

Regulatory note (sport): WADA-banned in regulated sport — explicitly named under Section S4.2 (Anti-Estrogenic Substances and SERMs) of the 2026 Prohibited List as a Specified Substance.[⁶]

Not DEA-scheduled.

SERM

Selective estrogen receptor modulator; a drug that blocks estrogen receptors in some tissues while acting estrogen-like in others.

Off-label use

Use of an approved drug for a condition or population not listed on its FDA-approved label.

Estradiol

The main form of estrogen; relevant in men because some testosterone is converted to estradiol.

Gynecomastia

Enlargement of breast tissue in males.

1. AstraZeneca Pharmaceuticals. Nolvadex (tamoxifen citrate) tablets prescribing information. US Food and Drug Administration. NDA 017970, originally approved December 30, 1977. Most recent label revision (s053) accessible at accessdata.fda.gov/drugsatfda_docs/label/2005/17970s053lbl.pdf.
2. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, Dimitrov NV, Wolmark N, Wickerham DL, Fisher ER, et al. (1989). A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. New England Journal of Medicine, 320(8):479–484 (February 23, 1989).(PMID 2644532)
3. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. (2013). Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. The Lancet, 381(9869):805–816 (March 9, 2013).(PMID 23219286)
4. Mannu GS, Sudul M, Bettencourt-Silva JH, Tsoti SM, Cunnick G, Ahmed SF. (2018). Role of tamoxifen in idiopathic gynecomastia: A 10-year prospective cohort study. The Breast Journal, 24(6):1043-1045.(PMID 30079473)
5. Wibowo E, Pollock PA, Hollis N, Wassersug RJ. (2016). Tamoxifen in men: a review of adverse events. Andrology, 4(5):776–788 (September 2016).(PMID 27152880)
6. World Anti-Doping Agency. The 2026 Prohibited List, International Standard (effective 1 January 2026). Canonical PDF: wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf (linked from the WADA landing page; local archival copy in `docs/legal/wada-2026-prohibited-list.pdf`). Tamoxifen is named explicitly under Section S4.2 (Anti-Estrogenic Substances and SERMs) — page 10 of the canonical PDF — as a Specified Substance. Verbatim from the canonical PDF: under S4.2 ("anti-estrogenic substances [anti-estrogens and selective estrogen receptor modulators (SERMS)], Including, but not limited to:"), the named compounds are Bazedoxifene, Elacestrant, Raloxifene, Clomifene, Fulvestrant, Tamoxifen, Cyclofenil, Ospemifene, and Toremifene. The S4 section header notes "Prohibited substances in classes S4.1 and S4.2 are Specified Substances." Prohibited at all times, in-competition and out-of-competition.

• HCG (Human Chorionic Gonadotropin) — discussed together in this entry's stacks section
• Clomiphene / Enclomiphene — discussed together in this entry's stacks section
• Testosterone — discussed together in this entry's stacks section
• Gonadorelin — discussed together in this entry's stacks section